GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced its development program for PerQseal ® ...
Vivasure Medical Ltd. has designed a sutureless and absorbable venous vessel closure for use following percutaneous cardiovascular procedures, such as transcatheter mitral valve or tricuspid valve ...
Please provide your email address to receive an email when new articles are posted on . The CHOICE-CLOSURE trial was presented by Mohamed Abdel-Wahab, MD, consultant cardiologist and head of the ...
GALWAY, Ireland--(BUSINESS WIRE)--Vivasure Medical ® (“Vivasure” or the “Company”), a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the closing ...
Approval brings proven technology of the MYNX family of products to mid-bore venous puncture sites, including electrophysiology procedures. MIAMI, July 9, 2024 /PRNewswire/ -- Cordis, a global leader ...
The AMBULATE Same-Day Discharge Clinical Study Series demonstrates safe and effective use of VASCADE MVP in three studies to date, with more than 800 AF ablation patients discharged the same calendar ...
Haemonetics Corporation HAE recently gained CE mark certification for the VASCADE vascular closure and VASCADE MVP venous vascular closure systems. The VASCADE system is intended for ‘small-bore’ ...
BOSTON, June 18, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE), a global medical technology company focused on delivering innovative solutions to drive better patient outcomes, has launched a ...
Vivasure Medical Ltd. has designed a sutureless and absorbable venous vessel closure for use following percutaneous cardiovascular procedures, such as transcatheter mitral valve or tricuspid valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results